Seegnal
Seegnal presents a paradigm shift in combating Adverse Drug Reactions and their impacts, including health consequences, economic repercussions in re-admissions and re-visits, and doctors' fatigue, as well as streamlining the prescription process at the point of care, by moving the industry from DDI standard (Drug to Drug Interaction) to a new Patient at the Core standard. The platform integrates seamlessly with any Electronic Medical Records (EMR) system to offer personalized medication recommendations, including Precision Medication, in real-time with an unparalleled accuracy rate of 98%. Seegnal’s Digital Co-Pilot presents the future of prescribing medications at the point of care.
Industries
Nr. of Employees
small (1-50)
Seegnal is currently seeking investment
Seegnal is seeking a growth-stage investment in the range of 1m-5m
Patents
Method, system, and predictive computing platform for generating a reduced patient-specific data subset of drug-related adverse reaction alerts
2020-12-22 • US-10872079-B1
View Details
Method, system, and predictive computing platform for generating a reduced patient-specific data subset of drug-related adverse reaction alerts
2020-12-22 • US-10872079-B1
View DetailsProducts
Point-of-care medication decision support platform
A real-time platform that scans prescription intents and patient data to detect, prioritize, and help resolve drug-related problems while recommending safer, formulary-aware alternatives; supports pharmacogenomic inputs and continuous screening of new results.
Point-of-care medication decision support platform
A real-time platform that scans prescription intents and patient data to detect, prioritize, and help resolve drug-related problems while recommending safer, formulary-aware alternatives; supports pharmacogenomic inputs and continuous screening of new results.
Expertise Areas
- Clinical decision support for medication safety
- Pharmacogenomics and precision medication integration
- EHR/EHR plug-in integration and interoperability
- Alert management and clinical workflow optimization
Key Technologies
- Real-time decision engine
- APIs and EHR plug-in architecture
- Microservices-based deployment
- AI/ML-driven alert prioritization
Key People
News & Updates
Discusses the use of Doxazosin in an 85-year-old elderly female and the associated risks.
Explores the use of Bezafibrate sustained release formulation in patients with impaired renal function.
Analyzes the common alerts for prescribing two medications belonging to the incretin family.
Seegnal's distributor in the UK, Digitals UK, has been awarded a framework contract by the UK government to sell Seegnal in the public sector.
Seegnal will present at the world's leading healthcare expo for innovation as part of the Israeli Export Institution booth.
Seegnal Poland has signed the first hospitals to pilot Seegnal and is waiting for more hospitals to join.
Discusses the use of Doxazosin in an 85-year-old elderly female and the associated risks.
Explores the use of Bezafibrate sustained release formulation in patients with impaired renal function.
Analyzes the common alerts for prescribing two medications belonging to the incretin family.
Seegnal's distributor in the UK, Digitals UK, has been awarded a framework contract by the UK government to sell Seegnal in the public sector.
Seegnal will present at the world's leading healthcare expo for innovation as part of the Israeli Export Institution booth.
Seegnal Poland has signed the first hospitals to pilot Seegnal and is waiting for more hospitals to join.